Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vonoprazan + itopride
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vonoprazan + itopride is an investigational combination therapy being evaluated for the treatment of functional dyspepsia (FD). Vonoprazan is a potassium-competitive acid blocker (PCAB) that provides potent and sustained suppression of gastric acid by inhibiting the H+/K+-ATPase pump. Itopride is a prokinetic agent with a dual mechanism of action involving dopamine D2 receptor antagonism and acetylcholinesterase inhibition, which enhances gastrointestinal motility. The combination is designed to address both acid-related and motility-related symptoms of FD, such as epigastric pain, postprandial fullness, and early satiety. It is currently being studied in the VIVA Trial (Vonoprazan vs Vonoprazan + Itopride in Functional Dyspepsia) sponsored by the Asian Institute of Gastroenterology in India.
- Other names
- vonoprazan and itopridevonoprazan-itopride combination
02
Targets
AcetylcholinesteraseATP4A (Potassium–transporting ATPase alpha chain 1)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on vonoprazan + itopride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vonoprazan + itopride.